Accell Clinical Research Expands the Use of the CTMS Platform by Flex Databases
Flex Databases, a company specialising in Professional Services Automation (PSA) for pharmaceutical industry, announced today that Accell Clinical Research are expanding the use of the Flex CTMS platform to include its innovative Project Management module.
Accell is a CRO headquartered in St. Petersburg, Russia and active in Russia, Ukraine and Baltic States.
"We have been working with Flex since July 2012," said Natalia Nayanova, Director of Clinical Operations and General Manager of Accell Clinical Research. "We are going through an active growth phase, and last year we decided that it was time to acquire a platform allowing us to standardise both our internal and external processes. We looked at the market and Flex Databases were the best available choice for us. Although many factors contributed to our decision (clinical trial experience of the Flex team, their knowledge of the CRO business, flexibility of their platform), we felt that the biggest advantage they brought was the Professional Services Automation functionality — the ability to manage all the aspects of running a service organisation together with the clinical trial process. We are extending the use of the Flex platform by licensing their Project Management module - this will allow us to have full visibility of our projects and have all the relevant information centrally available, in an environment configured for our needs."
"We are thrilled to be expanding our relationship with Accell," said Timur Galimov, Technical Director of Flex Databases. "It has been a pleasure to work with Accell who are a dynamic company open to innovation. We are glad to see them leverage the full potential of our platform by adding Project Management, gaining access to features such as bid grid tool, resource planning, dynamic Gantt tables and automated budget updates. Accell took an active role in the relationship, feeding back ideas to us and sharing our enthusiasm for cutting edge technology, and we are pleased to be a part of their success."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance